Movatterモバイル変換


[0]ホーム

URL:


SE0102067D0 - Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation - Google Patents

Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation

Info

Publication number
SE0102067D0
SE0102067D0SE0102067ASE0102067ASE0102067D0SE 0102067 D0SE0102067 D0SE 0102067D0SE 0102067 ASE0102067 ASE 0102067ASE 0102067 ASE0102067 ASE 0102067ASE 0102067 D0SE0102067 D0SE 0102067D0
Authority
SE
Sweden
Prior art keywords
neovascularization
prevention
intervertebral discs
tissues
local inflammation
Prior art date
Application number
SE0102067A
Other languages
Swedish (sv)
Inventor
Kjell Olmarker
Original Assignee
A & Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & Science Invest AbfiledCriticalA & Science Invest Ab
Priority to SE0102067ApriorityCriticalpatent/SE0102067D0/en
Publication of SE0102067D0publicationCriticalpatent/SE0102067D0/en
Priority to PCT/SE2002/001115prioritypatent/WO2002100387A1/en

Links

Classifications

Landscapes

Abstract

The use of an anti-angiogenetic substance for the production of a pharmaceutical preparation for prevention of neovascularization and/or neoinnervation of intervertebral discs and/or of tissues with local inflammation, in particular for prevention of chronic pain, such as chronic low back pain and chronic whiplash associated disorder, is disclosed. Said neovascularization and/or neoinnervation of intervertebral discs may be caused by spinal trauma. Also a method for prevention of neovascularization and/or neoinnervation of intervertebral discs and/or of tissues with local inflammation wherein a therapeutically effective amount of an anti-angiogenetic substance is administered to an individual is disclosed.
SE0102067A2001-06-112001-06-11 Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammationSE0102067D0 (en)

Priority Applications (2)

Application NumberPriority DateFiling DateTitle
SE0102067ASE0102067D0 (en)2001-06-112001-06-11 Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation
PCT/SE2002/001115WO2002100387A1 (en)2001-06-112002-06-10Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
SE0102067ASE0102067D0 (en)2001-06-112001-06-11 Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation

Publications (1)

Publication NumberPublication Date
SE0102067D0true SE0102067D0 (en)2001-06-11

Family

ID=20284441

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SE0102067ASE0102067D0 (en)2001-06-112001-06-11 Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation

Country Status (2)

CountryLink
SE (1)SE0102067D0 (en)
WO (1)WO2002100387A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2003232081B2 (en)*2002-07-032009-02-05Brandeis UniversityCentral airway administration for systemic delivery of therapeutics
MXPA05012275A (en)2003-05-132006-02-10Depuy Spine IncA method of treating degenerative disc disease.
US7429378B2 (en)2003-05-132008-09-30Depuy Spine, Inc.Transdiscal administration of high affinity anti-MMP inhibitors
US8273347B2 (en)2003-05-132012-09-25Depuy Spine, Inc.Autologous treatment of degenerated disc with cells
US7553827B2 (en)2003-08-132009-06-30Depuy Spine, Inc.Transdiscal administration of cycline compounds
US7344716B2 (en)2003-05-132008-03-18Depuy Spine, Inc.Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8361467B2 (en)2003-07-302013-01-29Depuy Spine, Inc.Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en)2003-11-262014-11-25DePuy Synthes Products, LLCLocal intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
ITRM20030601A1 (en)2003-12-242005-06-25Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
US7217425B2 (en)2004-07-232007-05-15Depuy Spine, Inc.Autologous coatings for implants
US8715733B2 (en)2004-07-232014-05-06DePuy Synthes Products, LLCEnhanced adipose tissue
US7399742B2 (en)2004-07-232008-07-15Depuy Spine, Inc.Anti-osteolytic therapy involving adiponectin
ITRM20050290A1 (en)2005-06-072006-12-08Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
US8986696B2 (en)2007-12-212015-03-24Depuy Mitek, Inc.Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
AU2009329811B2 (en)*2008-12-222016-02-25The University Of MelbournePain treatment
ES2533952T3 (en)2009-02-092015-04-16Morphosys Ag Production of oligoclonal mixtures of immunoglobulins in individual cells
EP2481751A1 (en)*2011-01-262012-08-01PharmaSurgics in Sweden ABHuman lactoferrin derived peptides
CN110613837A (en)*2019-10-242019-12-27内蒙古医科大学第二附属医院Application of TGF-beta in preparation of medicine for preventing or treating lumbar disc herniation

Also Published As

Publication numberPublication date
WO2002100387A1 (en)2002-12-19

Similar Documents

PublicationPublication DateTitle
SE0102067D0 (en) Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation
MXPA05008617A (en)Uses of anti-insulin-like growth factor i receptor antibodies.
RS52867B (en)Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
AU2003301190A1 (en)Administration of capsaicinoids
WO2006119958A3 (en)Use of flibanserin in the treatment of chronic pain
CA2404387A1 (en)Theanine compositions for promoting sleep
EA201170018A1 (en) Razagilin to change the flow of Parkinson's disease
ATE454140T1 (en) DOPAMINE AGONIST COMBINATION THERAPY WITH SEDATIVES TO IMPROVE SLEEP QUALITY
WO2006058140A3 (en)Capsaicinoid gel formulation and uses thereof
TW200640486A (en)Composition
DE60321929D1 (en) PHARMACEUTICAL COMPOSITIONS WITH DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES
BRPI0410721A (en) foamable pharmaceutical compositions and methods for treating a disorder
WO2003073981A3 (en)Novel of cytokine inhibitors
AU4741001A (en)Viscoelastics for use in middle ear surgery
WO2005037323A3 (en)Use of gro to treat or prevent inflammation
IL179206A0 (en)Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MX2009012109A (en)Anti-insomnia compositions and methods.
WO2005046593A3 (en)Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
WO2005081742A3 (en)Testosterone oral dosage formulations and associated methods
TW200635598A (en)Oral suspension comprising meloxicam
WO2004043378A3 (en)Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2004100893A3 (en)Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2001089536A3 (en)Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
MXPA02006511A (en)Complex comprising ocif and polysaccharide.
SE0101256D0 (en) Treatment of low back pain

[8]ページ先頭

©2009-2025 Movatter.jp